Chemoembolization of hepatocellular carcinoma: Results of a metaanalysis

Jean Francois H Geschwind, Douglas E. Ramsey, Michael A. Choti, Paul J. Thuluvath, Michael S. Huncharek

Research output: Contribution to journalArticle

Abstract

Transcatheter arterial chemoembolization is considered the mainstay of therapy for unresectable hepatocellular carcinoma. The purpose of this study was to assess the impact of such treatment on survival by performing a metaanalysis of all available randomized clinical trials comparing this form of therapy to supportive care. A MEDLARS search was conducted covering the years 1970 to 2002. Data analysis was performed according to methods described by Peto. The primary outcome of interest was the proportion of patients surviving 3 and 6 months after treatment. All analyses were performed on an intent-to-treat basis. A literature search yielded 1,100 citations, from which four met protocol-specified inclusion criteria. All studies contained an experimental and control arm totalling 268 patients. The odds ratio for 3- and 6-month survival were 1.31 (95% CI: 0.66-2.58) and 0.91 (95% CI: 0.49-1.68), which was not statistically significant. These data fail to show a survival advantage associated with therapeutic embolization versus supportive care alone in patients with unresectable hepatocellular carcinoma. Existing survival data from randomized controlled trials are of poor quality, and the paucity of patients in these trials eliminates the possibility of drawing meaningful conclusions regarding the effect of chemoembolization on patient survival from these studies.

Original languageEnglish (US)
Pages (from-to)344-349
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number4
DOIs
StatePublished - Aug 2003

Fingerprint

Hepatocellular Carcinoma
Survival
MEDLARS
Randomized Controlled Trials
Therapeutic Embolization
Therapeutics
Odds Ratio

Keywords

  • Hepatocellular carcinoma
  • Metaanalysis
  • Randomized controlled trials
  • Transcatheter arterial chemoembolization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemoembolization of hepatocellular carcinoma : Results of a metaanalysis. / Geschwind, Jean Francois H; Ramsey, Douglas E.; Choti, Michael A.; Thuluvath, Paul J.; Huncharek, Michael S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 4, 08.2003, p. 344-349.

Research output: Contribution to journalArticle

Geschwind, Jean Francois H ; Ramsey, Douglas E. ; Choti, Michael A. ; Thuluvath, Paul J. ; Huncharek, Michael S. / Chemoembolization of hepatocellular carcinoma : Results of a metaanalysis. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2003 ; Vol. 26, No. 4. pp. 344-349.
@article{b00a3d8698e64790a44792eacccae801,
title = "Chemoembolization of hepatocellular carcinoma: Results of a metaanalysis",
abstract = "Transcatheter arterial chemoembolization is considered the mainstay of therapy for unresectable hepatocellular carcinoma. The purpose of this study was to assess the impact of such treatment on survival by performing a metaanalysis of all available randomized clinical trials comparing this form of therapy to supportive care. A MEDLARS search was conducted covering the years 1970 to 2002. Data analysis was performed according to methods described by Peto. The primary outcome of interest was the proportion of patients surviving 3 and 6 months after treatment. All analyses were performed on an intent-to-treat basis. A literature search yielded 1,100 citations, from which four met protocol-specified inclusion criteria. All studies contained an experimental and control arm totalling 268 patients. The odds ratio for 3- and 6-month survival were 1.31 (95{\%} CI: 0.66-2.58) and 0.91 (95{\%} CI: 0.49-1.68), which was not statistically significant. These data fail to show a survival advantage associated with therapeutic embolization versus supportive care alone in patients with unresectable hepatocellular carcinoma. Existing survival data from randomized controlled trials are of poor quality, and the paucity of patients in these trials eliminates the possibility of drawing meaningful conclusions regarding the effect of chemoembolization on patient survival from these studies.",
keywords = "Hepatocellular carcinoma, Metaanalysis, Randomized controlled trials, Transcatheter arterial chemoembolization",
author = "Geschwind, {Jean Francois H} and Ramsey, {Douglas E.} and Choti, {Michael A.} and Thuluvath, {Paul J.} and Huncharek, {Michael S.}",
year = "2003",
month = "8",
doi = "10.1097/00000421-200308000-00007",
language = "English (US)",
volume = "26",
pages = "344--349",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Chemoembolization of hepatocellular carcinoma

T2 - Results of a metaanalysis

AU - Geschwind, Jean Francois H

AU - Ramsey, Douglas E.

AU - Choti, Michael A.

AU - Thuluvath, Paul J.

AU - Huncharek, Michael S.

PY - 2003/8

Y1 - 2003/8

N2 - Transcatheter arterial chemoembolization is considered the mainstay of therapy for unresectable hepatocellular carcinoma. The purpose of this study was to assess the impact of such treatment on survival by performing a metaanalysis of all available randomized clinical trials comparing this form of therapy to supportive care. A MEDLARS search was conducted covering the years 1970 to 2002. Data analysis was performed according to methods described by Peto. The primary outcome of interest was the proportion of patients surviving 3 and 6 months after treatment. All analyses were performed on an intent-to-treat basis. A literature search yielded 1,100 citations, from which four met protocol-specified inclusion criteria. All studies contained an experimental and control arm totalling 268 patients. The odds ratio for 3- and 6-month survival were 1.31 (95% CI: 0.66-2.58) and 0.91 (95% CI: 0.49-1.68), which was not statistically significant. These data fail to show a survival advantage associated with therapeutic embolization versus supportive care alone in patients with unresectable hepatocellular carcinoma. Existing survival data from randomized controlled trials are of poor quality, and the paucity of patients in these trials eliminates the possibility of drawing meaningful conclusions regarding the effect of chemoembolization on patient survival from these studies.

AB - Transcatheter arterial chemoembolization is considered the mainstay of therapy for unresectable hepatocellular carcinoma. The purpose of this study was to assess the impact of such treatment on survival by performing a metaanalysis of all available randomized clinical trials comparing this form of therapy to supportive care. A MEDLARS search was conducted covering the years 1970 to 2002. Data analysis was performed according to methods described by Peto. The primary outcome of interest was the proportion of patients surviving 3 and 6 months after treatment. All analyses were performed on an intent-to-treat basis. A literature search yielded 1,100 citations, from which four met protocol-specified inclusion criteria. All studies contained an experimental and control arm totalling 268 patients. The odds ratio for 3- and 6-month survival were 1.31 (95% CI: 0.66-2.58) and 0.91 (95% CI: 0.49-1.68), which was not statistically significant. These data fail to show a survival advantage associated with therapeutic embolization versus supportive care alone in patients with unresectable hepatocellular carcinoma. Existing survival data from randomized controlled trials are of poor quality, and the paucity of patients in these trials eliminates the possibility of drawing meaningful conclusions regarding the effect of chemoembolization on patient survival from these studies.

KW - Hepatocellular carcinoma

KW - Metaanalysis

KW - Randomized controlled trials

KW - Transcatheter arterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=0043064251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043064251&partnerID=8YFLogxK

U2 - 10.1097/00000421-200308000-00007

DO - 10.1097/00000421-200308000-00007

M3 - Article

C2 - 12902882

AN - SCOPUS:0043064251

VL - 26

SP - 344

EP - 349

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -